iBio (NYSE:IBIO) Upgraded by StockNews.com to “Sell” Rating

iBio (NYSE:IBIO) was upgraded by analysts at StockNews.com to a “sell” rating in a note issued to investors on Tuesday.

iBio Stock Performance

Shares of NYSE IBIO traded down $0.34 during midday trading on Tuesday, hitting $4.52. 285,632 shares of the company’s stock traded hands, compared to its average volume of 1,140,904. iBio has a 1 year low of $1.05 and a 1 year high of $6.89. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a fifty day moving average of $3.85 and a 200 day moving average of $2.92.

Insider Activity

In related news, Director David Arkowitz acquired 18,382 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was bought at an average cost of $2.72 per share, for a total transaction of $49,999.04. Following the purchase, the director now owns 18,382 shares in the company, valued at $49,999.04. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in iBio stock. Geode Capital Management LLC lifted its stake in shares of iBio, Inc. (NYSE:IBIO) by 52.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 83,797 shares of the company’s stock after acquiring an additional 28,775 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of iBio worth $205,000 at the end of the most recent reporting period. 7.90% of the stock is currently owned by institutional investors.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.